In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Calif. Safe Cosmetics Act

This article was originally published in The Rose Sheet

Executive Summary

California Department of Health Services' budget for Senate Bill 484 may be finalized this summer, "possibly by July," according to Linda Loretz, PhD, director for safety and regulatory toxicology for the Cosmetic, Toiletry and Fragrance Association. She presented during the Strategic Research Institute-sponsored Cosmeceuticals meeting in New York City June 8-9. Loretz noted several new positions have been filled to enforce the act, but it is unclear how many of those positions will make it past the budgeting process. Effective Jan. 1, 2007, SB 484 requires manufacturers of cosmetics subject to FDA regulation and sold in California to report to the DHS use of any chemical known to the state as causing cancer or reproductive toxicity (1"The Rose Sheet" Oct. 17, 2005, p. 3)...

You may also be interested in...



Cosmetics Industry Loses California Battle; Ingredient Bill Becomes Law

The Cosmetic, Toiletry and Fragrance Association will work with the California Department of Health Services to implement provisions of the California Safe Cosmetics Act, the association says. Despite rigorous opposition by CTFA, among others, Gov. Arnold Schwarzenegger (R) signed the bill into law Oct. 7

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014006

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel